Innovent Biologics Inc(IVBXF)

Description: Innovent Biologics, Inc. operates as a development-stage biopharmaceutical company in China. The company develops a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, and autoimmune and metabolic diseases. Its principal drug candidates, including Tyvyt (sintilimab), anti-PD-1 monoclonal antibody for the treatment of gastric cancer, solid tumors, and esophageal carcinoma; IBI-301, a rituximab biosimilar for the treatment of chronic lymphocytic leukemia and rheumatoid arthritis; IBI-303, an adalimumab biosimilar for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriasis; and IBI-305, a bevacizumab biosimilar for the treatment of oncology. The company has a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. Innovent Biologics, Inc. was founded in 2011 and is headquartered in Suzhou, China.

---

Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Ophthalmology Rheumatoid Arthritis Arthritis Monoclonal Antibody Psoriasis Leukemia Ulcer Ulcerative Colitis Metabolic Disease Crohn's Disease Carcinoma Rheumatology Biosimilar Colitis Psoriatic Arthritis Chronic Lymphocytic Leukemia Gastric Cancer Spondylitis Ankylosing Spondylitis Adalimumab Treatment Of Chronic Lymphocytic Leukemia Juvenile Idiopathic Arthritis Treatment Of Gastric Cancer Esophageal Carcinoma

---

Home Page: www.innoventbio.com

168 Dongping Street
Suzhou, 215123
China
Phone: 86 512 6956 6088

---

Officers

Exchange: PINK

Country: US

Currency: US Dollar ($)